ImmuneSpec offers a proprietary immunopeptidomics workflow (MAPPS) that uses advanced purification, ultrasensitive mass‑spectrometry analysis, and enhanced data processing to identify MHC-associated immunogenic peptides. The company’s core product is a commercial service offering for CROs, biotech, and pharmaceutical firms focused on vaccine target identification, neo‑antigen discovery, and immunogenicity testing of biologicals. The underlying methodology was developed at the Centre for Proteomics, a collaboration between the University of Antwerp and VITO, and the team includes academic experts. ImmuneSpec plans to use the recent seed funding to optimize its platform, roll out commercial services, establish lab facilities in Science Park Niel (Belgium), and hire lab technicians, project managers, and data scientists. The company positions its MAPPS analyses as significantly more comprehensive than standard MS methods, yielding higher immunopeptide purity and volumes to speed and de‑risk drug development programs. Financially, ImmuneSpec received a EUR 1.2m seed investment announced in March 2023 to accelerate commercialisation and scale operations.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2023